Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is set to continue its successful growth trajectory, with the recent acquisition of Naveris and plans for expanding into the lucrative oncology market. As the market leader in transplant testing, the company has a strong financial outlook, and the potential for significant revenue through its upcoming AlloHeme test provides further upside. While potential risks from competition and pricing should be monitored, CDNA's demand for services and initiatives to improve revenue cycle management suggest continued success for the company.

Bears say

CareDx is projected to exceed its 2027 LR target of $500 million, due to expected strong performance in its core transplant business and the addition of a new MRD business. However, there may be challenges in meeting revenue expectations from its AlloSure Kidney and AlloMap Heart tests, and continued education efforts will be needed to drive adoption of these solutions in the market. While reliance on the Epic platform is expected to drive growth, it will also result in significant investments for the company.

CareDx (CDNA) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 3 analysts, CareDx (CDNA) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.